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Lipid overload and adipocyte dysfunction are key to the development of insulin resistance and can be induced 
by a high-fat diet. CD1d-restricted invariant natural killer T (iNKT) cells have been proposed as mediators 
between lipid overload and insulin resistance, but recent studies found decreased iNKT cell numbers and 
marginal effects of iNKT cell depletion on insulin resistance under high-fat diet conditions. Here, we focused 
on the role of iNKT cells under normal conditions. We showed that iNKT cell–deficient mice on a low-fat 
diet, considered a normal diet for mice, displayed a distinctive insulin resistance phenotype without overt adi-
pose tissue inflammation. Insulin resistance was characterized by adipocyte dysfunction, including adipocyte 
hypertrophy, increased leptin, and decreased adiponectin levels. The lack of liver abnormalities in CD1d-null 
mice together with the enrichment of CD1d-restricted iNKT cells in both mouse and human adipose tissue 
indicated a specific role for adipose tissue–resident iNKT cells in the development of insulin resistance. Strik-
ingly, iNKT cell function was directly modulated by adipocytes, which acted as lipid antigen-presenting cells in 
a CD1d-mediated fashion. Based on these findings, we propose that, especially under low-fat diet conditions, 
adipose tissue–resident iNKT cells maintain healthy adipose tissue through direct interplay with adipocytes 
and prevent insulin resistance.
Introduction
More than one-third of the U.S. population has insulin resistance, 
a condition that is predominantly caused by obesity and is associ-
ated with adipocyte dysfunction together with chronic low-grade 
adipose tissue (AT) inflammation (1–3). Lipid-induced adipocyte 
dysfunction appears instrumental to the inflammatory response 
in AT (4), which is characterized by inflammasome activation 
(5) and the release of fatty acids and cytokines (adipokines) that 
impair insulin receptor signaling, ultimately resulting in the devel-
opment of metabolic syndrome (6–8).
Distinct mechanisms impart control of immune homeostasis 
within AT, some of which were recently uncovered. AT-resident 
Tregs together with eosinophils control the development of 
local inflammation by counteracting the influx of CD11c+ (M1) 
inflammatory macrophages, CD8+ T cells, CD4+ T cells, and 
B cells, thereby preventing AT inflammation and insulin resistance 
(9–16). How adipocyte dysfunction relates to immune homeosta-
sis, however, remains incompletely understood, and a self-reactive 
cell type involved in orchestrating immune homeostasis in AT has 
not yet been reported.
Various findings prompted us to study the role of lipid antigen–
reactive invariant natural killer T cells (iNKT) cells in controlling 
AT inflammation and insulin resistance. First, the abundance of 
lipid antigens in AT preeminently suits lipid-sensitive invariant 
T cells such as iNKT cells, as they are triggered to release immune-
polarizing cytokines by lipid/CD1d complex binding (17–19). Sec-
ond, CD1d-restricted iNKT cells have roles in multiple metabolic 
disease models, including type 1 diabetes mellitus (20–23). Third, 
many tissues harbor resident T cells that can respond to stress-
induced self molecules rather than foreign antigens and ensure a 
tissue-specific effector class (Th1, Th2, or tolerogenic) response 
(24). iNKT cells are known to fulfill this role in the liver, repre-
senting up to 40% of liver-resident T cells in mice (19). Fourth, we 
were intrigued by the apparent enrichment of iNKT cells in mouse 
and human AT compared with peripheral blood (our unpublished 
observations and refs. 25, 26), especially in lean mice and humans. 
Fifth, recent studies showed that under high-fat diet (HFD) condi-
tions, CD1d-restricted iNKT cell function only marginally affects 
the development of insulin resistance (26–28). Accordingly, we 
hypothesized that AT-resident CD1d-restricted iNKT cell function 
may be particularly relevant under normal diet conditions.
We employed CD1d-null and Jα18-null mice, antibody deple-
tion of iNKT cells in WT mice, and human AT to address the role 
of AT-resident CD1d-restricted iNKT cells. Our mouse-based 
data show a unique role for CD1d-restricted iNKT cells in the 
maintenance of healthy adipocytes and prevention of insulin 
resistance, especially under low-fat diet (LFD) conditions, con-
sidered a normal diet for mice (29). Furthermore, coculture of 
human CD1d-restricted iNKT cells with adipocytes revealed a 
potential mechanism linking adipocyte dysfunction to immune 
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cell homeostasis, showing that CD1d-proficient adipocytes can 
function as lipid APCs for iNKT cells.
Results
iNKT cell knockout and antibody-mediated depletion result in insulin resis-
tance in lean mice. We addressed the impact of CD1d-restricted iNKT 
cells on AT homeostasis and insulin resistance using CD1d-null 
(30) and WT C57BL/6 mice. The mice were fed normal chow until 
11 weeks of age, followed by 19 weeks of LFD or HFD. Weight gain, 
caloric intake, and epididymal fat pad weight were similar among 
the genotypes, for both LFD and HFD mouse groups (Figure 1, 
A–C). Strikingly, glucose tolerance measured via an intraperitoneal 
glucose tolerance test (IP-GTT) was clearly impaired in the CD1d-
null mice compared with their WT counterparts, especially under 
LFD conditions (Figure 1, D–G). Under HFD conditions, CD1d-
null mice showed higher insulin levels during the IP-GTT than 
their WT counterparts, but maintained comparable glucose levels 
(Figure 1, D–G), in accordance with previous studies (26–28). To 
corroborate these findings, we used of Jα18-null mice, which are 
selectively deficient in type 1 iNKT cells (31). These animals also 
showed impaired glucose tolerance after 18 weeks of LFD com-
pared with their WT counterparts (Figure 1, H and I) while main-
taining comparable body weight (data not shown).
The insulin resistance in lean CD1d-null and Jα18-null mice was 
confirmed using an established iNKT depletion model, compar-
ing antibody-treated (anti-NK1.1) with isotype control–treated 
LFD-fed WT mice (32, 33). Partial depletion of AT-resident iNKT 
cells resulted in impaired glucose tolerance compared with iso-
type control treatment (Figure 1, J and K, and Supplemental Fig-
ure 1A; supplemental material available online with this article; 
doi:10.1172/JCI62739DS1). When a gain-of-function approach 
was pursued by in vivo activation of iNKT cells in WT mice on 
LFD through injection of the CD1d-restricted iNKT cell ligand 
α-galactosyl ceramide (αGalCer), glucose tolerance did not 
improve (Supplemental Figure 2C and ref. 26), probably due to 
the fact that WT animals are highly insulin sensitive under LFD 
conditions. Taken together, these findings indicate that CD1d-
restricted iNKT cells protect against insulin resistance, especially 
in LFD-fed mice.
As iNKT cells reside not only in AT (Figure 2) but also in the 
liver, and both organs are critically involved in the regulation of 
whole-body lipid and glucose homeostasis (34), we investigated 
circulating lipids and liver function in CD1d-null mice, focusing 
on LFD conditions. While circulating triglycerides were slightly 
elevated in CD1d-null mice on a LFD, circulating FFA and choles-
terol levels were not (Supplemental Figure 1, B–D). More impor-
tantly, CD1d-null mice on a LFD showed none of the pathologi-
cal alterations that are associated with liver-mediated insulin 
resistance (35): neither liver histology, weight, and lipid content 
nor the liver enzymes aspartate aminotransferase (AST) and ala-
nine aminotransferase (ALT) and the liver inflammatory mark-
ers lipocalin-2 (Lcn2) and serum amyloid A (Saa2) were altered in 
CD1d-null mice on a LFD, compared with their WT counterparts 
(Supplemental Figure 1, E–K). In WT and CD1d-null mice under 
HFD conditions, though, liver pathology was observed; for some 
parameters, this was most pronounced in CD1d-null mice (Sup-
plemental Figure 1, E–K). These findings argue against a principal 
role for the liver in the insulin-resistant phenotype observed in 
LFD-fed CD1d-null and iNKT cell–depleted mice. We therefore 
focused on the role of AT-resident iNKT cells.
AT-resident iNKT cells show an antiinflammatory phenotype and are 
downregulated on a long-term HFD. AT-resident iNKT cells consti-
tute 5%–10% of the visceral AT–resident (VAT-resident) T lympho-
cyte pool, as indicated by αGC-loaded CD1d tetramer and TCRβ 
staining (Figure 2A). Compared with spleen-derived iNKT cells, 
which are predominantly CD4+ and clearly express NK1.1, AT-
resident iNKT cells exhibit a phenotype biased toward CD4/CD8 
double-negative (~70%) with reduced NK1.1 expression (~50%) 
(Figure 2, A, D, and E). Next, AT-resident iNKT cell cytokine pro-
duction was analyzed. AT-resident iNKT cells showed an antiin-
flammatory phenotype with high levels of intracellular IL-4 and 
IL-13 and lower levels of IFN-γ compared with splenic iNKT cells 
(Figure 2B). Production of all 3 cytokines was increased upon in 
vivo treatment with αGalCer, both in AT and splenic iNKT cells 
(Figure 2B). Functionality of AT-resident iNKT cells (i.e., cytokine 
production) was confirmed by ex vivo stimulation experiments 
(Supplemental Figure 2B). To address the contribution of iNKT 
cells to cytokine production in AT, we performed quantitative RT-
PCR analysis on AT from WT and CD1d-null mice. A decrease 
in Il4 and Il13 mRNA levels in particular was observed in CD1d-
null mice, indicating that iNKT cells contribute to the presence 
of these cytokines in AT (Figure 2C). We noticed a decrease in 
iNKT numbers in VAT and in subcutaneous AT (SCAT) in WT 
mice fed a HFD compared with a LFD (Figure 2F), which was 
not due to TCRβ downregulation (data not shown). In addition, 
reduced expression of signaling lymphocytic activation molecule 
f1 (SLAMf1) (36, 37) on the remaining iNKT cells was observed 
(Supplemental Figure 2A). Thus, low iNKT cell numbers and 
activity under HFD conditions may partly explain the relatively 
small differences in glucose tolerance observed between WT and 
CD1d-null mice on a long-term HFD.
CD1d-null mice exhibit enhanced AT Treg numbers, preventing wors-
ening of insulin resistance. We next asked whether iNKT cells pre-
vent the insulin resistance in CD1d-null mice on a LFD through 
an immune-modulatory mechanism, as shown in other tis-
sues (17–19). Under HFD conditions, AT infiltration of CD8+ 
T cells, followed by infiltration of macrophages that exhibit an 
M1-polarized phenotype, plays a pivotal role in the development 
of insulin resistance (13, 38). However, CD1d-null mice on a 
LFD exhibited neither AT CD8+ T cell infiltration nor increased 
macrophage numbers and M1 polarization (Figure 3, A and B, 
and Supplemental Figure 3A). Only under HFD conditions did 
we observe increased macrophage numbers and M1 polarization 
in CD1d-null mice compared with their WT counterparts (Sup-
plemental Figure 3, A and B). Instead, higher CD4+CD25+ T cell 
numbers were detected in AT of CD1d-null mice, on both LFD 
and HFD (Figure 3C and Supplemental Figure 3B). CD4+CD25+ 
T cells extracted from AT expressed high levels of Foxp3 (Fig-
ure 3D), and the number of CD4+Foxp3+ T cells (but not their 
MFI) was increased in the iNKT cell–depleted mice (Figure 3E 
and data not shown). Thus, complete absence of iNKT cells in 
CD1d-null mice and antibody-mediated iNKT cell depletion 
both result in an enrichment of Tregs in AT. Considering the 
protective role of Tregs in AT (9), we next addressed whether the 
increased Treg numbers prevent worsening of the insulin resis-
tance phenotype. Upon anti-CD25 antibody–mediated deple-
tion of Tregs in the CD1d-null mice on a LFD, an aggravation of 
the insulin-resistant phenotype observed in CD1d-null mice was 
seen (Figure 3, F and G, and Supplemental Figure 3C). Point-
ing to the importance of iNKT cells for this effect, depletion 
Downloaded on May  2, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/62739
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 122   Number 9   September 2012 3345
Figure 1
iNKT cell knockout and antibody-
mediated depletion result in insulin 
resistance in lean mice. For A–H, 
n = 10 mice per group; total 40 mice. 
(A) Weight gain of WT and CD1d-null 
mice on the LFD and HFD regimens. 
Mice were weighed weekly. (B) Week-
ly caloric intake of WT and CD1d-null 
mice on the LFD and HFD regimens. 
(C) Epididymal fat pad weights of the 
WT and CD1d-null mice on a LFD 
and HFD regimen, measured after 
termination. (D and E) IP-GTTs were 
performed after 17 weeks of LFD or 
HFD. Plasma glucose concentrations 
and the AUC for the various groups 
are shown. (F and G) Plasma insulin 
levels during the IP-GTT are shown, 
together with the AUC. (H and I) IP-
GTT of WT and Jα18-null mice after 
18 weeks of LFD. Shown are plasma 
glucose concentrations and the AUC 
for the 2 groups. n = 15 mice per 
group; total 30 mice. (J and K) IP-
GTT of WT (Isotype) and iNKT cell–
depleted (αNK1.1) WT mice. Note that 
this antibody also depletes NK cells. 
Shown are plasma glucose concen-
trations and the AUC for the 2 groups. 
n = 10 mice per group; total 20 mice. 
*P < 0.05.
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of Tregs in the WT mice on a LFD had no effect (Supplemental 
Figure 3D). Taken together, the results indicated that CD1d-
null mice on a LFD have a unique AT phenotype that, unlike the 
well-studied HFD phenotype, is characterized not by increased 
influx of proinflammatory CD8+ T cell or macrophage popula-
tions, but rather by increased Treg numbers. The increase in AT 
Tregs observed upon iNKT cell depletion may serve to prevent 
further aggravation of insulin resistance.
Absence of CD1d-restricted iNKT cells is associated with adipocyte dys-
function in lean mice. Using an Affymetrix microarray platform, 
we explored further the AT phenotype in CD1d-null mice on a 
LFD. Microarray analysis underscored that the AT phenotype 
Figure 2
AT-resident iNKT cells show an activated phenotype and are downregulated on a long-term HFD. (A) Stromal vascular fraction of visceral adipose 
tissue (VAT) from WT and CD1d-null mice was stained for TCRβ, CD1d tetramer, CD4, and CD8. FSC, forward scatter; SSC, side scatter. Num-
bers in graphs indicate the percentage of cells in that gate. Second and third panel, percentage of TCRβ+ cells; fourth panel, CD4 and CD8 stain-
ing of iNKT cells. (B) Intracellular staining of spleen and visceral AT-extracted iNKT cells from 4 WT mice, injected intraperitoneally with αGalCer 
(5 µg) or vehicle. Shown are representative histograms and averages in bar graphs. (C) Quantitative RT-PCR on VAT of WT and CD1d-null mice 
on the LFD and HFD regimens. n = 9 mice per group; total 36 mice. (D and E) Percentage of CD4–CD8– and NK1.1+ iNKT cells (gated on TCRβ 
and CD1d/αGC-loaded tetramer) extracted from spleen and VAT of WT mice on a LFD. n = 10 mice per group; total 20 mice. (F) Number of iNKT 
cells per gram of SCAT and VAT of WT mice on LFD and HFD regimens. n = 10 mice per group; total 20 mice. *P < 0.05.
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in lean insulin-resistant CD1d-null mice is different from the 
HFD-associated disease pattern. Classical inflammatory markers 
upregulated under HFD conditions, including Tnfa, Emr1 hor-
mone receptor (F4/80), integrin alpha X (Cd11c), Ccl2, serum amy-
loid a 3 (Saa3), and a disintegrin and metallopeptidase domain 8 
(Adam8) (39–41) were not different in LFD-fed CD1d-null mice 
and their WT counterparts (Figure 4, A and B). The effect of long-
term HFD on the transcriptional profile was remarkably similar 
in both genotypes (Supplemental Figure 4), in accordance with 
the reduced AT-resident iNKT numbers detected under long-
term HFD conditions (Figure 2F). Next, we focused on adipocyte 
function in LFD-fed CD1d-null mice. Along with inflamma-
tory changes, adipocyte dysfunction, characterized by adipocyte 
hypertrophy and altered adipokine secretion (1), is key to the 
development of insulin resistance. Indeed, enlarged adipocytes 
(larger area per adipocyte and lower number of adipocytes per 
field) were found in the CD1d-null mice on a LFD compared with 
their WT counterparts (Figure 4C and Supplemental Figure 4C), 
but there was no difference in epididymal fat pad weight (Figure 
1C) or total fat mass as determined by dual energy X-ray absorpti-
ometry (DEXA) scanning (Supplemental Figure 4D). 
No changes in several genes involved in lipogenesis 
(stearoyl-coenzyme A desaturase 1, Scd1; fatty acid 
synthase, Fas), lipid droplet formation (perilipin 1, 
Lipin1, Pparg), and thermogenesis (uncoupling 
protein 1, Ucp1; Ppara) were detected in LFD-fed 
CD1d-null mice, except for a significant increase in 
lipin (Supplemental Figure 4E), an adiposity gene 
involved in triglyceride synthesis (42). Lipolysis, as 
determined by plasma glycerol levels, was also not 
significantly changed (Supplemental Figure 4F). 
Remarkably, the adipocyte dysfunction in LFD-fed 
CD1d-null mice was reflected by decreased levels of 
the insulin-sensitizing adipokine adiponectin and 
increased levels of the insulin-desensitizing leptin 
(43), at both the mRNA level in the AT and the pro-
tein level in the plasma (Figure 4, D and E). Thus, 
development of insulin resistance in the absence of 
iNKT cells may originate from adipocyte dysfunc-
tion, in particular altered adipokine secretion.
Enrichment of CCR2+ iNKT cells in human AT. Having investigated 
mouse AT-resident iNKT cells, we set out to study the role of 
iNKT cells in human AT. We first assessed the relative number 
of iNKT cells as a fraction of lymphocytes in paired blood and 
abdominal SCAT samples obtained from healthy donors (n = 6). 
iNKT cell numbers were enriched approximately 10-fold in 
AT compared with blood (flow cytometry analyses, using TCR 
Vα24/Vβ11 and CD3/αGC-loaded CD1d tetramer staining) 
(Figure 5, A and B). In AT and blood, 30% of the iNKT popula-
tion consisted of CD4+ iNKT cells, with the remaining fraction 
mostly representing CD4–CD8– iNKT cells (Figure 5, A and C). 
We considered the possibility that iNKT cells are recruited 
to AT. To this end, we determined the expression of a range of 
chemokine receptors on iNKT cells purified from blood and AT, 
including CCR2, CCR4, CCR5, CCR7, CXCR2, CXCR3, CXCR6, 
and CX3CR1, as well as CD62L and CD11b (44). Significantly 
increased expression levels on iNKT cells from AT compared 
with blood were observed for CCR2, the chemokine receptor for 
the AT-secreted MCP-1 (45), and for the chemokine receptors 
CXCR2 and CXCR6, while expression levels of the other chemo-
Figure 3
CD1d-null mice exhibit enhanced AT Treg numbers, pre-
venting worsening of insulin resistance. (A–C) n = 10 
mice per group; total 20 mice. (A) Number of CD8+ T cells 
(TCRβ+) per gram of SCAT and VAT, for WT and Cd1d–/– 
mice on a LFD. (B) Number of macrophages (F4/80+) per 
gram of SCAT and VAT, and percentage of M1-polarized 
(CD11c+) macrophages for WT and Cd1d–/– mice on a 
LFD. (C) Number of CD4+CD25+ T cells (TCRβ+) per 
gram of SCAT and VAT for WT and Cd1d–/– mice on a 
LFD. (D) Representative results of staining of Foxp3 and 
CD25 expression on AT-derived CD4+ T cells (TCRβ+) in 
Cd1d–/– mice. (E) Number of Tregs (TCRβ+CD4+Foxp3+) 
per gram of VAT for WT (Isotype) and iNKT cell–depleted 
(αNK1.1) WT mice. n = 10 mice per group; total 20 mice. 
(F and G) IP-GTT of Cd1d–/– (Isotype) and Treg-depleted 
(αCD25) CD1d-null mice on a LFD. Shown are plasma 
glucose and insulin concentrations, together with the 
AUC for the 2 groups. n = 10 mice per group; total 20 
mice. *P < 0.05.
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kine receptors and CD62L and CD11b were similar in iNKT cells 
from AT and blood (Figure 5D and Supplemental Figure 5A). 
Thus, MCP-1/CCR2–mediated and CXCR2- and CXCR6-medi-
ated chemotaxis may provide a mechanism for the recruitment 
of iNKT cells to AT.
Human adipocytes express Cd1d and can regulate iNKT cell function. 
Adipocytes are a major constituent of AT and contain lipids that 
may serve as CD1d antigenic ligands. Therefore, we tested the 
possibility that adipocytes directly modulate iNKT cell function 
by presenting lipid antigens. First, the expression of CD1d and its 
Figure 4
Absence of CD1d-restricted iNKT cells is associated with adipocyte dysfunction in lean mice. (A) Microarray-based fold change versus fold 
change scatter plot comparing gene expression profiles in WT HFD group (x axis) and Cd1d–/– LFD group (y axis). Genes of interest encoding 
classical inflammatory markers or adipokines are highlighted in red (upregulated) or blue (downregulated). Fold changes represent the mean of 
4–6 mice per experimental group. (B) Quantitative RT-PCR of selected classical inflammatory markers in AT. Mean expression in WT LFD mice 
was set at 1. Fold changes were normalized for housekeeping gene expression (36B4). n = 9 mice per group; total 27 mice. (C) H&E staining of 
VAT from WT and CD1d-null mice after 19 weeks of LFD feeding. Scale bars: 100 µm. VAT adipocyte sizes (area per adipocyte, µm2) in LFD-fed 
WT and CD1d-null mice are presented. Box plots show the median area per adipocyte for both groups, and 10th to 90th percentiles. n = 10 mice 
per group; total 20 mice. (D and E) Leptin and adiponectin mRNA expression in VAT were determined by quantitative RT-PCR (n = 9 mice per 
group; total 27 mice). Leptin and adiponectin protein levels were analyzed in plasma from LFD-fed CD1d-null mice and WT mice on a LFD and 
HFD. n = 10 mice per group; total 30 mice.
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lipid-loading machinery was analyzed in human SGBS (pre)adi-
pocytes, a well-established adipocyte cell culture model (46), and 
in human primary adipocytes by quantitative RT-PCR. Several 
known components required for antigen loading (pro-saposin, 
NPC2, α-galactisodase) as well as CD1D itself were expressed at 
background levels in undifferentiated preadipocytes, but were 
readily detectable in mature human SGBS adipocytes and pri-
mary adipocytes (Figure 6A). Of note, CD1d depletion by lenti-
virally transduced CD1d shRNA in human preadipocytes did not 
influence their differentiation potential, adipocyte marker expres-
sion, or adiponectin secretion, suggesting that CD1d expression 
is not essential for differentiation and function of cultured (pre)
adipocytes (Supplemental Figure 5, B and C). The upregulation 
of CD1d and its loading machinery as measured by increased 
mRNA gene transcription in mature human adipocytes suggests 
that adipocytes can function as lipid APCs for iNKT cells. To test 
this possibility, we generated short-term iNKT cell lines (>70% 
CD1d-restricted iNKT cells) from 5 healthy blood donors (47) 
and cocultured them with human adipocyte cell lines, where indi-
cated displaying reduced CD1d expression upon shRNA-mediat-
ed knockdown or overexpressing CD1d (Supplemental Figure 5B 
and Supplemental Figure 6A). After loading of mature adipocytes 
with αGalCer (48) and 18 hours of coculture, the production of 
IL-4, IL-13, and IFN-γ by the iNKT cells was assessed. Strikingly, 
iNKT cells cocultured with mature adipocytes showed the high-
est intracellular IL-4, IL-13, and IFN-γ levels. The intracellular 
cytokine levels were found to be reduced upon CD1d blocking 
and depleted to background levels by CD1d knockdown (Figure 
6B and Supplemental Figure 6B). Interestingly, basal cytokine 
levels were also decreased by CD1d knockdown, suggesting that 
adipocytes can present lipid autoantigens (Figure 6B and Sup-
plemental Figure 6B). Cytokine measurements in the superna-
tant were affirmative, again showing only IL-4, IL-13, and IFN-γ 
release for iNKT cells cocultured with mature adipocytes. Also 
here cytokine release was reduced upon CD1d blocking and fully 
depleted by CD1d knockdown (Figure 6C and Supplemental Fig-
Figure 5
Enrichment of CCR2+ iNKT cells in human AT. (A) Blood and AT-derived iNKT cells were stained for Vα24, Vβ11, CD1d tetramer, and CD4 and 
CD8 expression. iNKT cell percentages of the total CD3+ population are shown. For B–D, n = 6 healthy donors. (B and C) iNKT cell contribution to 
the total CD3+ T cell population in blood and AT, and the percentage of CD4+ and CD4/CD8 double negative iNKT cells. (D) Chemokine receptor 
and CD62L expression on blood and AT-derived iNKT cells (gated on CD3 and CD1d/αGC-loaded tetramer). *P < 0.05.
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ure 6C). Taken together, our results show that mature human 
adipocytes express functional CD1d and can act as lipid APCs, 
modulating iNKT cell function.
Discussion
In recent years, various AT-resident immune cells have been impli-
cated in the regulation of lipid and glucose homeostasis (9, 13, 14). 
Here we show that AT-resident CD1d-restricted iNKT cells protect 
against the development of insulin resistance by preventing adipo-
cyte dysfunction, especially under LFD conditions. The high num-
bers of CD1d-restricted iNKT cells in both mouse and human AT 
raise three interesting questions.
First, why do iNKT cells accumulate in AT? The abundance of 
lipid antigens, together with the lipid APC function of CD1d-
proficient adipocytes, may contribute importantly to this phe-
nomenon. In mouse and human liver, lipid processing and high 
CD1d expression by various cell types also create an iNKT niche 
(48, 49). Moreover, the enrichment of CCR2+ iNKT cells in human 
Figure 6
Adipocytes can modulate iNKT cell function in a CD1d-dependent manner. (A) Quantitative RT-PCRs of CD1d and its lipid-loading machinery 
genes pro-saposin, NPC2, and α-galactosidase in human SGBS preadipocytes, mature adipocytes, and primary subcutaneous adipocytes iso-
lated from 3 human subjects. HLA-B mRNA levels were included as a negative control. Fold changes were normalized for housekeeping genes 
(36B4 and β2 actin). (B) Intracellular IL-4 staining of iNKT cells cocultured with undifferentiated SGBS preadipocytes and mature adipocytes, 
with and without prior loading of the (pre)adipocytes with the CD1d-restricted iNKT cell ligand αGalCer. CD1d knockdown in the adipocytes 
depleted intracellular IL-4 staining in the cocultured iNKT cells. (C) IL-4, IL-13, and IFN-γ levels in the supernatants of iNKT cells cocultured with 
undifferentiated SGBS preadipocytes and mature adipocytes. Antibody blocking and CD1d knockdown of CD1d in mature adipocytes result in 
a significant decrease in IL-4, IL-13, and IFN-γ levels in the supernatants, while CD1d overexpression results in an increase. Data represent the 
mean results of 5 different iNKT cell lines cocultured with the (pre)adipocytes. *P < 0.05.
Downloaded on May  2, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/62739
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 122   Number 9   September 2012 3351
Finally, iNKT cells are known to bridge innate and adaptive 
immunity, as they can rapidly release high doses of immune polar-
izing cytokines upon lipid/CD1d complex binding (17–19). Upon 
prolonged stimulation, iNKT cell numbers are known to decrease 
and iNKT cells become anergic (62). This physiological role of 
iNKT cells, together with the insulin-resistant phenotype of CD1d-
null iNKT cell–deficient mice under LFD conditions, supports a 
key role for AT-resident iNKT cells as a first line of defense against 
adipocyte dysfunction, AT inflammation, and insulin resistance. 
Importantly, AT-resident iNKT cell function seems to depend on 
diet composition, duration of the diet, and possibly also indige-
nous gut microbiota (63). The protective role of iNKT cells appears 
most explicit under long-term LFD conditions, as Kotas et al. 
recently failed to observe a protective role of iNKT cells under 
normal chow conditions in 7- to 10-week-old mice (28). The anti-
inflammatory phenotype of AT-resident iNKT cells we observed 
under unstimulated conditions, with high IL-4 and IL-13 produc-
tion, together with the strong upregulation of IFN-γ production 
upon stimulation with the exogenous lipid antigen αGalCer, fuels 
the hypothesis that AT-resident iNKT cell function is determined 
by dietary factors, possibly in combination with AT lipid autoan-
tigens. The capacity of adipocytes to modulate iNKT cell function 
in a CD1d-mediated fashion offers a tempting adipocyte-centered 
perspective on the mechanisms behind iNKT cell activation. CD1d-
dependent adipocyte–iNKT cell interactions may play a key role in 
the maintenance of healthy AT under LFD conditions.
Methods
Animal studies. WT C57BL/6J mice (8 weeks; Charles River), CD1d-null 
mice (30), and Jα18-null mice (31) that had been backcrossed to C57BL/6J 
for 10–12 generations were age matched and fed standard chow until age 
10–11 weeks and subsequently fed a LFD (10 kcal% fat; Research Diets, 
D12450B) or HFD (45 kcal% fat; Research Diets, D12451) for 18–19 weeks. 
For the IP-GTT, mice (age 28 weeks) were fasted overnight, glucose was 
injected intraperitoneally (0.5 g/kg body weight), and blood glucose levels 
were measured before and at multiple time points after glucose injection 
(Accu-chek, Roche). Plasma was frozen at multiple time points for insu-
lin measurements. For the iNKT cell and Treg depletion studies (Figure 
1, J and K, Figure 3, F and G, Supplemental Figure 1A, and Supplemental 
Figure 3C), WT C57BL/6J mice (8 weeks; Charles River) were fed standard 
chow until age 10 weeks and subsequently fed LFD for 6 weeks. In the fifth 
week of LFD feeding, weight-matched groups received 3 intraperitoneal 
injections of 300 µg αNK1.1 antibody (clone PK136), 3 injections of 
250 µg αCD25 antibody (clone PC61), or isotype antibody injections, in 
agreement with established iNKT and Treg depletion models (32, 64). 
(Note that the αNK1.1 antibody also depletes NK cells.) In the sixth week of 
LFD feeding, all mice underwent an IP-GTT (1 g/kg body weight glucose) 
before sacrifice. For the in vivo challenge with αGalCer, WT C57BL/6J mice 
(10 weeks) fed LFD for 18 weeks were injected intraperitoneally with either 
vehicle (PBS; n = 10) or αGalCer (n = 10) and underwent an IP-GTT (1 g/kg 
body weight glucose) 3 days afterward. For DEXA, fat mass was measured 
by DEXA scan under general anesthesia (isoflurane/N2O/O2) using a 
PIXImus imager (GE Lunar).
Isolation of mouse leukocytes and flow cytometry. Murine visceral (epididy-
mal) and subcutaneous AT was collected, washed in PBS, and digested for 
45 minutes with collagenase type II (Sigma-Aldrich) and DNAse I (Roche). 
Stromal vascular cells (SVCs) were pelleted by centrifugation, incubated 
for 20 minutes with NH4Cl erythrocyte lysis buffer, and passed through a 
100-µm cup filter (BD). Simultaneously, spleens were minced through a 
70-µm mesh filter (BD) and collected in NH4Cl lysis buffer. Subsequently, 
AT suggests chemotaxis by AT-secreted MCP-1, reminiscent of AT-
resident macrophages (50). The plethora of AT-secreted factors 
(43) may well include additional molecules affecting chemotaxis, 
proliferation, and function of AT-resident iNKT cells.
Second, are liver or muscle, as important regulators of glucose 
tolerance along with AT, involved in the insulin resistance observed 
in CD1d-null mice? LFD-fed CD1d-null mice showed none of the 
pathological alterations associated with liver-mediated insulin 
resistance. A primary role for muscle tissue, another key regulator 
of whole-body insulin sensitivity, also seems unlikely, as iNKT cell 
numbers in muscle appear to be low (51). Nevertheless, we can-
not exclude secondary roles for the liver and muscle in the insulin 
resistance following CD1d deficiency. As in obesity, the adipocyte 
dysfunction in the LFD-fed CD1d-null mice, characterized by adi-
pocyte hypertrophy and altered adipokine secretion, may well affect 
the insulin sensitivity of secondary tissues such as liver and muscle 
(1, 43). We have thereby come to the third question.
What function do iNKT cells exert in AT? Our results indicate 
that iNKT cells should be included in the list of AT-resident 
immune cells mediating glucose tolerance: AT-resident macro-
phages (15, 16), T cells (9, 13, 14), B cells (52), eosinophils (10), 
and mast cells (53). AT-resident iNKT cells appear to be unique, 
though, in their communication with adipocytes. The expres-
sion of functional CD1d in adipocytes and modulation of iNKT 
cell function fuel the hypothesis that adipocytes, via lipid pre-
sentation to iNKT cells, exert control over the local immune 
response in AT (24). Similar to other tissues (54), iNKT cells 
may exert immunoregulatory roles in concert with AT-resident 
Tregs. Indeed, the increased Treg numbers in AT upon deple-
tion or knockdown of iNKT cells suggest partial compensation 
of the iNKT loss by Tregs. Accordingly, depletion of AT-resident 
Tregs in CD1d-null mice on a LFD aggravated the already exist-
ing insulin resistance. The adipocyte dysfunction in CD1d-null 
mice observed here, however, also fuels an alternative hypothesis. 
Along with indirectly affecting adipocyte function via immune 
modulation, iNKT cells may also directly control adipocyte 
function: the iNKT cytokine IL-4, secreted at high levels by AT-
resident compared with spleen-derived iNKT cells, is known 
to improve insulin sensitivity via STAT6 activation (55). IL-13, 
which is also produced by AT-resident iNKT cells under basal 
conditions, may also affect adipocyte function, but this area has 
not been explored so far. Interestingly, we found that AT-resi-
dent iNKT cells are also capable of producing IFN-γ when stimu-
lated with αGalCer. As IFN-γ has been associated with insulin 
resistance in cultured adipocytes (56, 57) and in vivo (14, 58), 
these findings suggest that, in contrast to the protective role we 
observed under LFD conditions, iNKT cells could contribute to 
the development of insulin resistance under other conditions. 
Indeed, some recent reports indicate that depletion of iNKT cells 
can improve insulin sensitivity under HFD conditions (59–61). 
The exact role of iNKT cells under HFD conditions is, however, 
unclear, as other studies, and the present study, failed to detect 
a prominent effect of iNKT cell depletion on glucose homeosta-
sis (26–28). Of note, the decreased number of AT-resident iNKT 
cells in obese human individuals and in mice under long-term 
HFD conditions may explain the marginal effects of iNKT cell 
depletion under HFD conditions (refs. 25, 26, and the present 
study). Future studies are required to establish the exact roles of 
iNKT-produced cytokines in mediating adipocyte (dys)function 
and insulin resistance under HFD conditions.
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Adipocyte morphometry, AT and liver immunohistochemistry, and liver 
triglycerides. Morphometry of individual adipocytes was performed as 
described (69). H&E staining of AT and liver sections was performed using 
standard protocols. Oil red O (ORO) stock solution was prepared by dis-
solving 0.5 g ORO (Sigma-Aldrich, O-0625) in 100 ml isopropanol. ORO 
working solution was prepared by mixing 30 ml ORO stock with 20 ml 
dH2O, followed by filtration. Sections (5 µm) were cut from frozen liver 
sections embedded in O.C.T. Sections were air dried for 30 minutes, fol-
lowed by fixation in 4% formaldehyde for 10 minutes (4% formaldehyde). 
Sections were immersed in ORO working solution for 15 minutes, fol-
lowed by 2 rinses with dH2O. Hematoxylin staining of nuclei was subse-
quently carried out for 5 minutes, followed by several rinses with dH2O. 
Sections were mounted in aqueous mountant (Imsol).
Liver triglycerides were determined in liver homogenates prepared in 
buffer containing 250 mM sucrose, 1 mM EDTA, and 10 mM Tris-HCl at 
pH 7.5 using a commercially available kit (Instruchemie) according to the 
manufacturer’s instructions.
Human subjects. Human abdominal subcutaneous AT samples and blood 
(sodium heparin) were obtained from 6 healthy female donors during elective 
abdominoplastic surgery in Bergman Beauty Clinics, Bilthoven, the Nether-
lands. Immune cell isolations were performed immediately after surgery.
Isolation of human lymphocytes and flow cytometry. SCAT was collected and 
finely minced, washed in DPBS (Invitrogen), and digested with collagenase 
type II (Sigma-Aldrich) and DNAse I (Roche). SVCs were filtered over a 
100-µm cup filter (BD) and pelleted by centrifugation. After NH4Cl eryth-
rocyte lysis, SVCs were filtered over a 50-µm cup filter (BD) and pelleted by 
centrifugation. Simultaneously, PBMCs were isolated from the patients’ 
blood as described previously (70). SVCs and PBMCs were washed in FACS 
buffer, preincubated with 10% mouse serum in FACS buffer, and stained 
with mAbs specific for Vα24, Vβ11, CD3, CD4, CD8, CD56, CD95, and 
a CD1d tetramer (NIH). Furthermore, adhesion factor and chemokine 
receptor expression was studied with mAbs specific for CD62L, CD11b, 
CCR2, CCR4, CCR5, CCR7, CXCR2, CXCR3, CXCR6, and CX3CR1. Cells 
were analyzed by flow cytometry as described above.
Human adipocytes, lentiviral overexpression, and knockdown of human CD1d. 
The human preadipocyte SGBS cell line was cultured and differenti-
ated into adipocytes as described previously (46, 71). Full-length cDNA 
encoding human CD1d was cloned into a pLenti CMV vector (Addgene). 
The shRNA construct for human CD1d was provided in a pLKO.1 vector 
(Sigma-Aldrich, clone NM_001766.2-814s1c1). Lentiviral particles were 
produced in 293T cells. After lentiviral infection, SGBS preadipocytes were 
kept on 2 µg/ml puromycin. Stably transduced cells were used for the adi-
pocyte–iNKT cell interaction studies.
The adiponectin secretion of SGBS adipocytes transduced with empty 
vector and CD1d shRNA constructs was measured making use of a recently 
developed and validated multiplex immunoassay (72).
(Pre)adipocyte–iNKT cell interaction study. Untransduced, CD1d shRNA–
transduced, and CD1d-overexpressing human SGBS (pre)adipocytes were 
incubated with αGalCer for 24 hours and with and without CD1d block-
ing antibody (1 µg/ml CD1d mAb clone 51.1, BioLegend) for 1 hour. Sub-
sequently, iNKT cell lines (>70% CD1d-restricted iNKT cells) from 5 differ-
ent blood donors, generated as described previously (47), were incubated 
with the preadipocytes and adipocytes for 18 hours in RPMI medium 
(Invitrogen) supplemented with 10% human AB+ serum, 100 µg penicil-
lin/ml, and 100 µg streptomycin/ml (Invitrogen) and IL-2 (10 U/ml). For 
the last 6 hours, media were supplemented with 0.1% GolgiStop (BD). 
Finally, the suspended iNKT cell fraction was pelleted for intracellular 
cytokine staining, and the supernatant was stored at –80°C until analysis 
of cytokine levels. Cytokine levels were measured with a cytokine multiplex 
immunoassay, as described recently (72).
AT SVCs and spleen cells were washed in FACS buffer (2% fetal calf serum 
and 0.1% NaN3 in PBS); preincubated with 10% rat serum in FACS buf-
fer; and stained with mAbs specific for TCRβ, NK1.1, CD3, CD8, CD4, 
CD25, and a CD1d tetramer (NIH) for lymphocyte phenotyping (for some 
samples, this was followed by intranuclear staining of Foxp3) or stained 
with mAbs for CD206, F4/80, TCRβ, a CD1d tetramer (NIH), CD150, and 
CD11c for macrophage phenotyping. Cells were analyzed by flow cytom-
etry with a FacsCanto II (BD) flow cytometer and FACSDiva (BD) and 
FlowJo (Tree Star Inc.) software.
αGalCer stimulation of iNKT cells for intracellular staining. WT C57BL/6J 
mice (10 weeks) received an intraperitoneal injection of either 5 µg αGalCer 
(n = 4) or vehicle (n = 4). The next day, the mice were sacrificed, and AT 
SVCs and spleen cells were extracted and dissolved in RPMI medium con-
taining 10% fetal calf serum, 1% penicillin/streptomycin, and 0.1% Golgi-
Plug (BD) for 2 hours. Subsequently, after preincubation with 10% rat 
serum in FACS buffer, cells were stained with mAbs for TCRβ, NK1.1, and 
a CD1d tetramer (NIH) to identify the iNKT cells, followed by intracellular 
staining for IL-4 (BD), IFN-γ (BD), IL-13 (BioLegend), and the correspond-
ing isotype antibodies to determine intracellular iNKT cytokine levels.
Ex vivo stimulation and intracellular cytokine staining of AT-resident iNKT cells. 
Extracted AT SVCs and spleen cells of WT C57Bl/6J mice (9 weeks, n = 4) 
were dissolved in RPMI medium including 10% fetal calf serum and 1% pen-
icillin/streptomycin, and incubated with 5 ng/ml PMA, 1 µg/ml ionomycin, 
and 0.1% GolgiStop (BD) for 4 hours. Subsequently, intracellular cytokine 
levels were measured as described above for the αGalCer stimulation.
RNA extraction, quantitative PCR, and microarray analysis. Snap-frozen 
epididymal AT was homogenized and RNA was extracted using TRIzol 
(Invitrogen). RNA was purified on an RNeasy Micro column (QIAGEN), 
RNA integrity was checked with a Bioanalyzer (Agilent), and cDNA syn-
thesis was performed with iScript (Bio-Rad). Quantitative PCR with SYBR 
Green (Bio-Rad) was run on a MyiQ machine (Bio-Rad). Primers for quan-
titative RT-PCR were designed with the universal probe library (Roche) 
and are described in Supplemental Table 1. Microarray experiments were 
performed as described before (65). RNA samples from 4–6 mice per experi-
mental group were used for microarray analysis. One hundred nanograms 
of RNA per sample was hybridized to an Affymetrix GeneChip Mouse Gene 
1.1 ST 24 array plate according to the manufacturer’s instructions. Arrays 
were normalized with the robust multiarray average (RMA) method (66, 
67). Probe sets were defined according to Dai et al. (68) with CDF version 
13.0.2 based on Entrez identifiers. The probes present on these arrays tar-
get 21,212 unique genes. Genes were only taken into account if the intensi-
ty value was greater than 20 on at least 3 arrays and the interquartile range 
of the intensity values was greater than 0.1 (log2) across the experiment. 
These criteria were met by 14,444 genes. Microarray data have been submit-
ted to the Gene Expression Omnibus database (GEO number GSE39534).
Mouse plasma measurements. Mouse EDTA plasma was harvested after cen-
trifugation and stored at –80°C until analysis. Mouse plasma adipokines 
were measured with Milliplex mouse adipokine kits (Millipore), according 
to the manufacturer’s instructions. Measurements and data analysis were 
performed on a Bio-Plex system in combination with Bio-Plex manager 
software version 4.1.1 (Bio-Rad). AST and ALT levels in mouse EDTA plas-
ma were measured at the diagnostic laboratory of the University Medical 
Centre Utrecht with a Beckman Coulter DxC chemistry analyzer.
Plasma lipoproteins were separated using fast protein liquid chroma-
tography (FPLC). Pooled plasma (0.2 ml) was injected into a Superose 6B 
10/300 column (GE Healthcare Life Sciences) and eluted at a constant 
flow of 0.5 ml/min with PBS (pH 7.4). The effluent was collected in 
0.5-ml fractions and FFA, triglyceride, and cholesterol levels were deter-
mined (Instruchemie). Plasma glycerol was measured with a commercially 
available kit from Instruchemie.
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